SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementi... See more
Feb, 1, 2023
This will bring in billions of revenue and it will... See more
SLRX
Salarius Pharmaceuticals Inc
-8.52%
$2.23 - $2.04
Feb 8th 2023 - Mar 22nd 2023
Nov, 10, 2022
$SLRX 'We believe this interim data is an e... See more
Oct, 28, 2022
$SLRX “These initial data explain why we believ... See more
BXRX
Baudax Bio Inc
-52.79%
$3.41 - $1.61
Feb 7th 2023 - Mar 21st 2023
Feb, 13, 2023
“We believe the use of BX1000, combined with our r... See more
Dec, 17, 2022
This could be significantly impactful for patients... See more
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”
Feb, 1, 2023
This will bring in billions of revenue and it will make the life quality longer for AD patients.
Jan, 29, 2023
This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.
Jan, 18, 2023
CURING LEUKEMIA isn't a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!
Jan, 11, 2023
$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete
Jan, 9, 2023
The high number of the patients that went into CMS (which is 80% complete) is reassuring.
Jan, 6, 2023
but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!
Dec, 30, 2022
but mostly new hope for all the families and patients with AZ.
Dec, 29, 2022
Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.
Nov, 10, 2022
$SLRX 'We believe this interim data is an encouraging development for these patients in need of new treatment options and we are looking forward to an additional data update next month.”
Oct, 28, 2022
$SLRX “These initial data explain why we believe SP-3164 is so exciting, with the potential to make a positive difference in the treatment of hematologic cancers.
Feb, 13, 2023
“We believe the use of BX1000, combined with our reversal agent, BX3000, could make for precise control of timing under neuromuscular paralysis for surgical patients, which could result in time and cost savings for patients and hospitals alike.
Dec, 17, 2022
This could be significantly impactful for patients, surgeons, and anesthesiologists by enhancing safety, and possibly saving time and reducing costs related to delayed recovery from neuromuscular paralysis following surgical procedures.”
Dec, 9, 2022
It's a miracle drug for patients that suffer with cronic osteoarthritis.
Dec, 9, 2022
It is a game changer for heart patients and is being rapidly adopted by hospitals and doctors.